<DOC>
	<DOCNO>NCT00110981</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness combination therapy etanercept narrow-band ( NB ) UVB phototherapy treatment psoriasis pilot study . This Phase 4 clinical study conduct Amgen Investigational New Drug Application ( IND ) .</brief_summary>
	<brief_title>Utilization Narrow Band Ultraviolet B ( UVB ) Light Therapy Etanercept Treatment Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Chronic plaque psoriasis eligible systemic therapy NBUVB opinion investigator Psoriasis Activity Severity Index ( PASI ) great equal 15 least 25 % individual plaque must consider severe Patients must body surface area ( BSA ) involvement great equal 5 % Before studyspecific procedure , subject must sign date appropriate write informed consent Negative urine pregnancy test within 7 day first dose study drug woman ( except surgically sterile least 5 year postmenopausal ) Sexually active subject childbearing potential must agree use medically acceptable form contraception screen throughout study Prior phototherapy Current prior treatment tumor necrosis factor ( TNF ) antagonist , include etanercept , infliximab adalimumab Erythrodermic , pustular guttate psoriasis Evidence skin condition ( e.g. , eczema ) psoriasis would interfere studyrelated evaluation psoriasis Evidence active infection fever , chill , sweat , history untreated Lyme disease active severe infection within 4 week screen visit screen baseline visit History immune compromise health [ e.g. , human immunodeficiency virus ( HIV ) positive status ] History cutaneous malignancy time , include squamous basal cell carcinoma melanoma History noncutaneous cancer within 5 year Actinic keratosis atypical mole History alcohol drug abuse within 12 month screen visit Current enrollment another clinical study treatment another experimental drug approve therapy experimental use within 30 day prior etanercept administration Severe comorbidities outline ENBREL ( r ) Package Insert : diabetes mellitus require insulin , congestive heart failure severity , myocardial infarction ( within less equal 52 week screen ) , unstable angina pectoris , oxygendependent severe pulmonary disease , tuberculosis tuberculosis exposure , chronic hepatitis B hepatitis C , systemic lupus erythematosus , history multiple sclerosis demyelinate disease , transverse myelitis , optic neuritis epilepsy , uncontrolled hypertension ( define systolic blood pressure great 180 mm Hg diastolic blood pressure great 110 mm Hg ) Contraindications accord ENBREL ( r ) Package Insert Evidence open cutaneous ulcer Evidence photosensitivity disorder ( e.g. , polymorphous light eruption ) Nursing mother , female subject plan become pregnant male subject plan pregnancy spouse/partner study Subjects commit assessment require protocol Known photosensitivity know sensitivity excipients product administer dose Any disorder compromise ability subject give write informed consent and/or comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>dermatology</keyword>
	<keyword>plaque psoriasis</keyword>
	<keyword>skin</keyword>
	<keyword>etanercept</keyword>
	<keyword>ENBREL</keyword>
	<keyword>NB-UVB , narrow-band UVB , phototherapy</keyword>
	<keyword>combination therapy , 50 mg prefilled syrinx</keyword>
</DOC>